Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ
between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed
on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two
enoxaparin dosing strategies.